Recently our group demonstrated that higher levels of IL-6 and CXCL10 were significantly associated with poor disease-free survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab plus oxaliplatin-based regimens [37]. This evidence concerns the gene CXCL10 and metastatic colorectal cancer.